RecruitingPhase 3NCT07100730

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Intervention
TLX-101-Tx + Lomustine(combination_product)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
2025 – 2027

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07100730 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma →

← Back to all trials